Rochelle Stenzler, B.Sc.Phm., ICD.D

Chair of the Board of Directors; Former Board Chair, Cynapsus Therapeutics; Former President Touchlogic, TLC, Revlon Canada, Pharma Plus Drugmarts; Former Vice Chair, Humber River Hospital

Rochelle Stenzler has a distinguished business career as both a board director and senior executive, including serving as the Chair of the Board of Cynapsus Therapeutics (NASDAQ: CYNA), until it was acquired for C$841M by Sunovion Pharmaceuticals. She currently serves as an Advisory Board member of Social Capital Partners.

She has extensive experience as a senior executive in healthcare, retailing, consumer packaged goods, and IVR technology. Rochelle's executive leadership roles include being President & CEO of TouchLogic Corporation; President, International Operations of TLC Laser Eye Centers Inc.; President of Revlon Canada Inc.; and President & General Manager of Pharma Plus Drugmarts Ltd.

Rochelle is originally a pharmacist by education and training. She is a graduate of the University of Toronto with a Bachelor of Science in Pharmacy and a Gold Medal in Compounding and Dispensing, and the Rotman School of Management, Institute of Corporate Directors, with an ICD.D.

Arun Menawat

CEO, Profound Medical; Former CEO, Novadaq

Dr. Arun Menawat is the CEO of Profound Medical Inc., a medical technology company that is developing a real-time MRI-guided thermal ultrasound system for incision-free ablation of abnormal or cancerous tissue. Prior to joining Profound, Arun served as the President and CEO of Novadaq Technologies Inc. for 13 years, guiding the company from a start-up to one of the fastest-growing, NASDAQ listed medical technology companies in North America, with a market cap of over $1 Billion USD.

Arun also serves as a member of the board of directors of Stereotaxis Inc. and ElMindA Ltd. and as an advisor to Baylis Medical. He obtained a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, he was named the EY Ontario Entrepreneur of the Year in the health sciences category.

Maryscott Greenwood

Partner and U.S. Managing Director, Crestview Strategy; CEO, Canadian American Business Council

Maryscott (Scotty) Greenwood is a Crestview Strategy Partner and the U.S. Managing Director. Scotty assists clients with their legislative and public policy challenges in Canada and the United States. She holds a BA in Political Science from the University of Vermont.

As CEO of the Canadian-American Business Council, she has repeatedly been recognized by Canadian newsweekly The Hill Times, which has named her one of the country's "Top 100 Lobbyists" (2017), "Top 100 People Influencing Canadian Foreign Policy" (2014) and "Top 100 Most Influential People in Government and Politics" (2010). She previously served as a Principal at Dentons from July 2015 to June 2019 and as a Senior Managing Director at McKenna, Long & Aldridge LLP from April 2001 to June 2015. Scotty has also served as a Director on the Board of Tilray since its successful NASDAQ IPO in July 2018.

In 2001, Scotty spent four years as chief of staff of the US Embassy in Canada, having been offered the diplomatic posting by President Clinton. During this time, she received the State Department's Meritorious Honor Award for her innovative outreach program to US governors and Canada's premiers to foster cooperation on issues of mutual concern.

Jamie Spiegelman

Co-Founder and Director, Spartan Bioscience; Internal Medicine and Critical Care Specialist, Humber River Hospital

Dr. Jamie Spiegelman is a senior staff doctor at Humber River Regional Hospital in the Departments of Internal Medicine and Critical Care Medicine. He has also served as the President of the Medical Staff Association, Hospital Board Director, and Foundation Director of Humber River Hospital.

Dr. Spiegelman has been involved in numerous healthcare and technology startups in a variety of roles including as a co-founder, inventor, advisor, principal investigator, and board director with companies such as Plexagen Diagnostics, Spartan Bioscience, and Lobo Genetics.

Dr. Spiegelman also has extensive clinical, research, and laboratory experience including with Peter Oefner and Ronald W. Davis at Stanford University's Genome Technology Center. He has been published in numerous scientific journals on a variety of research topics including.

Dr. Spiegelman has a BSc in Human Biology and a Medical Degree from the University of Toronto. He completed his fellowship in Intensive Care Medicine at the University of Toronto.

Seymour Liebman

Executive Vice President, Chief Administrative Officer and General Counsel of Canon U.S.A., Inc.

Mr. Liebman joined Canon U.S.A. Accounting Division in 1974 as a Manager and was promoted to Vice President in 1987. In 1989, he established the in-house legal department at Canon U.S.A. In addition, Mr. Liebman was appointed Chief Administrative Officer in 2008, and oversaw all legal affairs and corporate administration functions for Canon Americas. He is also Senior Managing Executive Officer of Canon Inc., Japan, and Chairman of BriefCam, Ltd. From 2011-2012, Mr. Liebman was President of Canon Information and Imaging Solutions.

Mr. Liebman earned his Bachelor of Arts in mathematics from Hofstra University, a Master's Degree in mathematics from Rutgers University, a Master’s Degree in accounting from Long Island University, and a JD from Touro Law School. He received an Honorary Doctorate from Hofstra University and gave the keynote address at graduation in May 2016. He is a Certified Public Accountant and an Attorney admitted in New York, New Jersey, and Washington, D.C.

Roger Eacock

Chief Executive Officer, Spartan Bioscience Inc.

Roger Eacock is Spartan's Chief Executive Officer. Roger is a seasoned leader with extensive experience in transformations and fast-growth companies, including TerrAscend, Sobeys, SunOpta, and Dell. Roger's broad experience in manufacturing and scaling operations globally will be critical as Spartan's moves towards the delivery execution phase of its COVID-19 test system. Roger's previous strategic turnaround leadership is the featured subject of an MBA case study at the Harvard School of Business. Roger is a member of the Royal Canadian Navy CLaS (Canadian Leaders at Sea) organization. He has also previously participated in two committees of the United Nations Global Compact, and has worked with Al Gore's Climate Reality Project since 2008.